CoChat

Ocular toxicity due to Trametinib and Dabrafenib

Open access
Sarny, Stephanie, Neumayer, Michael, Kofler, Julian, El-Shabrawi, Yosuf · 2017 · BMC Ophthalmology

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND: To report a case of uveitis and neuroretinal detachment in a patient treated with Trametinib and Dabrafenib due to metastatic cutaneous melanoma stage IV. CASE PRESENTATION: We evaluated slit lamp examination, fundoscopy, optical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suffering visual loss. Fundoscopy showed serous neuroretinal detachment of the fovea accompanied with white spots surrounding the fovea in both eyes. Although therapy with Trametinib and Dabrafenib was stopped uveitis anterior was seen 2 weeks later. After a year, the therapy was started again and the serous neuroretinal detachment appeared once more, however without inflammatory reaction of the anterior chamber. CONCLUSION: Patients treated with Trametinib and Dabrafenib should undergo consecutive eye examinations from the beginning of the therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12886-017-0541-0

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Optical coherence tomography of the right eye at first examination under therapy with Dabrafenib and Trametinib
Fig. 1 Optical coherence tomography of the right eye at first examination under therapy with Dabrafenib and TrametinibCC BY · PubMed Central
Fig. 2 Fluorescein angiography of the right eye at first examination under therapy with Dabrafenib and Trametinib
Fig. 2 Fluorescein angiography of the right eye at first examination under therapy with Dabrafenib and TrametinibCC BY · PubMed Central
Fig. 3 Indocyanine green angiography of the right eye at first examination under therapy with Dabrafenib and Trametinib
Fig. 3 Indocyanine green angiography of the right eye at first examination under therapy with Dabrafenib and TrametinibCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 64

Metadata

Authors
Sarny, S., Neumayer, M., Kofler, J., & El-Shabrawi, Y.
Affiliations
Klinikum Klagenfurt (AT)
Corresponding author
Sarny, Stephanie
Venue
BMC Ophthalmology
Published
2017-08-17
Volume
17
Issue
1
Pages
146-146
ISSN
1471-2415 (ISSN-L)
OpenAlex
W2748159422
Cited by
61
References
12
Citations by year
2025: 3 · 2024: 9 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 7 · 2019: 9 · 2018: 2
FWCI
4.80
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Ophthalmology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
trametinib, dabrafenib, ocular toxicity, uveitis, metastatic cutaneous melanoma, vision loss, fundus examination
MeSH terms
Aged, Antineoplastic Agents, Humans, Imidazoles, Male, Oximes, Pyridones, Pyrimidinones, Retinal Detachment, Uveitis, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ocular toxicity due to Trametinib and Dabrafenib. https://app.cochat.ai/papers/10.1186/s12886-017-0541-0
The paper
Sarny, S., Neumayer, M., Kofler, J., & El-Shabrawi, Y. (2017). Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmology. https://doi.org/10.1186/s12886-017-0541-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.